前列腺癌雄激素剥夺治疗男性的肝病风险
基于SEER-Medicare数据库1992至2009年82,938例66岁及以上局限性前列腺癌男性,排除既存非酒精性脂肪性肝病、肝病、糖尿病或代谢综合征者后,采用倾向评分校正的竞争风险回归比较接受与未接受雄激素剥夺治疗者的肝病风险;37.5%接受该治疗,其非酒精性脂肪性肝病、肝硬化、肝坏死及任何肝病诊断风险均升高,且治疗剂量数与结局呈剂量-反应关系。
要点
- 雄激素剥夺治疗与前列腺癌男性非酒精性脂肪性肝病诊断风险升高相关。
- 肝硬化、肝坏死及任何肝病诊断风险亦升高。
- 雄激素剥夺治疗剂量数与非酒精性脂肪性肝病及任何肝病呈剂量-反应关系。
核心结论
- 前列腺癌男性的雄激素剥夺治疗与非酒精性脂肪性肝病的诊断相关。
- 观察性研究设计存在常规局限性,包括在人群登记中定义结局可能不准确。
研究设计与样本
- 研究纳入SEER-Medicare数据库1992至2009年66岁及以上、诊断为局限性前列腺癌的82,938例男性。
- 排除既存非酒精性脂肪性肝病、肝病、糖尿病或代谢综合征的男性。
- 采用倾向评分校正的竞争风险回归模型比较接受与未接受雄激素剥夺治疗者的非酒精性脂肪性肝病风险。
- 探索雄激素剥夺治疗累积暴露的影响,以促性腺激素释放激素激动剂/拮抗剂的月度等效剂量计算(少于7、7至11或超过11剂)。
主要发现
- 总体37.5%的男性接受了雄激素剥夺治疗。
- 接受雄激素剥夺治疗者更可能被诊断为非酒精性脂肪性肝病(HR 1.54,95%CI 1.40-1.68)。
- 接受雄激素剥夺治疗者更可能被诊断为肝硬化(HR 1.35,95%CI 1.12-1.60)。
- 接受雄激素剥夺治疗者更可能被诊断为肝坏死(HR 1.41,95%CI 1.15-1.72)。
- 接受雄激素剥夺治疗者更可能被诊断为任何肝病(HR 1.47,95%CI 1.35-1.60)。
关键数值与推荐
- 非酒精性脂肪性肝病:HR 1.54,95%CI 1.40-1.68。
- 肝硬化:HR 1.35,95%CI 1.12-1.60。
- 肝坏死:HR 1.41,95%CI 1.15-1.72。
- 任何肝病:HR 1.47,95%CI 1.35-1.60。
- 雄激素剥夺治疗累积暴露按促性腺激素释放激素激动剂/拮抗剂月度等效剂量分为少于7、7至11或超过11剂。
临床怎么用
- 对接受雄激素剥夺治疗的前列腺癌男性,应关注非酒精性脂肪性肝病及其他肝病的诊断风险。
- 雄激素剥夺治疗累积剂量较高者可能需更关注肝病风险。
局限性
- 观察性研究设计存在常规局限性。
- 在人群登记中定义结局可能存在不准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Androgen deprivation therapy is associated with the development of diabetes and metabolic syndrome. To our knowledge its effect on the development of nonalcoholic fatty liver disease, a condition which frequently co-occurs with metabolic syndrome and other subsequent liver conditions such as liver cirrhosis, hepatic necrosis or any liver disease, has not been investigated. MATERIALS AND METHODS: We identified 82,938 men 66 years old or older who were diagnosed with localized prostate cancer in the SEER (Surveillance, Epidemiology and End Results)-Medicare database from 1992 to 2009. Men with preexisting nonalcoholic fatty liver disease, liver disease, diabetes or metabolic syndrome were excluded from study. Propensity score adjusted, competing risk regression models were created to compare the risk of nonalcoholic fatty liver disease in men who were vs were not treated with androgen deprivation. We also explored the influence of cumulative exposure to androgen deprivation therapy, calculated as monthly equivalent doses of gonadotropin-releasing hormone agonists/antagonists (fewer than 7, 7 to 11 or more than 11 doses). RESULTS: Overall 37.5% of men underwent androgen deprivation therapy. They were more likely to be diagnosed with nonalcoholic fatty liver disease (HR 1.54, 95% CI 1.40-1.68), liver cirrhosis (HR 1.35, 95% CI 1.12-1.60), liver necrosis (HR 1.41, 95% CI 1.15-1.72) and any liver disease (HR 1.47, 95% CI 1.35-1.60). A dose-response relationship was observed between the number of androgen deprivation therapy doses, and nonalcoholic fatty liver disease and any liver disease. CONCLUSIONS: Androgen deprivation therapy in men with prostate cancer is associated with the diagnosis of nonalcoholic fatty liver disease. The usual limitations of an observational study design apply, including possible inaccuracy in defining outcomes in a population based registry.
引用
- Gild P, Cole AP, Krasnova A, et al. Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. J Urol. 2018. PMID: 29673944. doi:10.1016/j.juro.2018.03.135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。